Development of a broad-spectrum epitope-based vaccine against Streptococcus pneumoniae
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0317216 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Md Nahian und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Jagannath University, Dhaka, Bangladesh. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Pneumococcal Infections, Epitopes, Pneumococcal Vaccines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Streptococcus pneumoniae (SPN) is a significant pathogen causing pneumonia and meningitis, particularly in vulnerable populations like children and the elderly. Available pneumonia vaccines have limitations since they only cover particular serotypes and have high production costs. The emergence of antibiotic-resistant SPN strains further underscores the need for a new, cost-effective, broad-spectrum vaccine. Two potential vaccine candidates, CbpA and PspA, were identified, and their B-cell, CTL, and HTL epitopes were predicted and connected with suitable linkers, adjivant and PADRE sequence. The vaccine construct was found to be antigenic, non-toxic, non-allergenic, and soluble. The three-dimensional structure of the vaccine candidate was built and validated. Docking analysis of the vaccine candidate by ClusPro demonstrated robust and stable binding interactions between the MEV and toll-like receptor 4 in both humans and animals. The iMOD server and Amber v.22 tool has verified the stability of the docking complexes. GenScript server confirmed the high efficiency of cloning for the construct and in-silico cloning into the pET28a (+) vector using SnapGene, demonstrating successful translation of the epitope region. Immunological responses were shown to be enhanced by the C-IMMSIM server. This study introduced a strong peptide vaccine candidate that has the potential to contribute to the development of a rapid and cost-effective solution for combating SPN. However, experimental verification is necessary to evaluate the vaccine’s effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Jagannath University, Dhaka, Bangladesh.
- State Key Laboratories of Chemical Resources Engineering, Beijing University of Chemical Technology, Beijing, China.
- Computational Biology Research Laboratory, Department of Pharmacy, Daffodil International University, Dhaka, Bangladesh.
- Bangladesh Council of Scientific and Industrial Research (BCSIR), Dhaka, Bangladesh.
- Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil.
ORCID-Profile: Md Nahian, Shopnil Akash, Shahina Akter
Zitieren
APA
Nahian, M., Shahab, M., Khan, M. R., Akash, S., Banu, T. A., Sarkar, M. H., Goswami, B., Chowdhury, S. F., Islam, M. A., Abu Rus'd, A., Begum, S., Habib, A., Shaikh, A. A., Oliveira, J. I. N., & Akter, S. (2025). Development of a broad-spectrum epitope-based vaccine against Streptococcus pneumoniae. PLOS ONE. https://doi.org/10.1371/journal.pone.0317216
Vancouver
Nahian M, Shahab M, Khan MR, Akash S, Banu TA, Sarkar MH, et al. Development of a broad-spectrum epitope-based vaccine against Streptococcus pneumoniae. PLOS ONE. 2025. doi:10.1371/journal.pone.0317216
BibTeX
@article{Nahian2025,
author = {Nahian, Md and Shahab, Muhammad and Khan, Md Rasel and Akash, Shopnil and Banu, Tanjina Akhtar and Sarkar, Murshed Hasan and Goswami, Barna and Chowdhury, Sanjana Fatema and Islam, Mohammad Ariful and Abu Rus'd, Ahmed and Begum, Shamima and Habib, Ahashan and Shaikh, Aftab Ali and Oliveira, Jonas Ivan Nobre and Akter, Shahina},
title = {Development of a broad-spectrum epitope-based vaccine against Streptococcus pneumoniae},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0317216}
}
EUVIMED